VEGFA and neoplasm: CMs derived from different types of cells have been modified for targeted drug delivery, for example, VEGF-modified red blood CMs such as nanoshells (V-RZCD) can escape immune recognition [102] and platelet membranes for tumor-targeting NPs in multiple cancer engineering [213, 214].